文献速递炎症性肠病

克罗恩病术后管理策略与长期手术复发的趋势:ENEIDA登记数据

Time Trends in Strategies for Postoperative Crohn's Disease Management and Long-Term Surgical Recurrence: Estudio Nacional en Enfermedad Inflamatoria Intestinal Sobre Determinantes Genéticos y Ambientales (ENEIDA) Registry Data.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-07-15

基于西班牙ENEIDA登记中1990-2020年接受首次回结肠切除术的4890例成人克罗恩病患者,按手术年代分为生物制剂前时代、早期生物制剂时代和广泛生物制剂时代。结果显示,硫唑嘌呤和生物制剂用于术后复发医学预防的比例显著增加,生物制剂治疗术后复发也增加,且5年和10年累积无手术复发生存率在后期队列中显著更高。

要点

  • 近20年克罗恩病术后复发的医学预防显著增加,硫唑嘌呤和生物制剂使用均上升。
  • 生物制剂用于治疗术后复发亦增加,与累积手术复发概率显著下降相关。
  • 早期和广泛生物制剂时代的5年和10年无手术复发生存率均高于生物制剂前时代。

核心结论

  • 过去20年克罗恩病首次肠切除术后复发的医学预防显著增加,同时生物制剂用于治疗术后复发也增加,这些变化与手术复发累积概率显著下降相关。

研究设计与样本

  • 基于西班牙ENEIDA登记数据的回顾性队列研究,纳入1990-2020年间接受首次回结肠切除术的成人克罗恩病患者4890例。
  • 按手术日期分为生物制剂前时代(1990-2000,23%)、早期生物制剂时代(2000-2010,38%)和广泛生物制剂时代(2011-2020,39%)。

主要发现

  • 硫唑嘌呤用于术后复发医学预防的比例:生物制剂前时代12%,早期47%,广泛37%(P < .001)。
  • 生物制剂用于术后复发医学预防的比例:生物制剂前时代0%,早期9%,广泛37%(P < .001)。
  • 生物制剂用于治疗术后复发的比例:生物制剂前时代35%,早期48%,广泛43%(P < .001)。
  • 5年和10年累积无手术复发生存率:生物制剂前时代92%和83%,早期96%和90%,广泛97%和91%(P < .001)。

临床怎么用

  • 临床可参考趋势,对克罗恩病首次回结肠切除术后患者更积极考虑医学预防,包括硫唑嘌呤和生物制剂。
  • 术后复发治疗中生物制剂使用增加与手术复发减少相关,支持在术后管理中合理使用生物制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The availability of biologicals has been associated with a decreased rate of first intestinal resection in patients with Crohn's disease (CD). However, its impact on postoperative recurrence (POR) has received little attention. We aimed to assess time trends in the strategies for the management of postoperative CD and the rate of second surgeries over the past 3 decades. METHODS: Adult patients with CD who had undergone a first ileocolic resection between 1990 and 2020 were identified from the Spanish Estudio nacional en Enfermedad Inflamatoria Intestinal sobre determinantes genéticos y ambientales (ENEIDA) registry. Patients were grouped by date of surgery as follows: before the biological era ([BB] 1990-2000), in the early biological era ([EB] 2000-2010), and in the widespread biological era ([WB] 2011-2020). RESULTS: A total of 4890 patients were included (23% BB, 38% EB, and 39% WB). A significant increase in medical prevention of POR with both thiopurines (BB, 12%; EB, 47%; and WB, 37%; P < .001) and biological agents (BB, 0%; EB, 9%; and WB, 37%; P < .001) was observed. Medical treatment with biologicals for POR also increased (BB, 35%; EB, 48%; and WB, 43%; P < .001). The cumulative surgical POR-free survival rate at 5 and 10 years was significantly higher in both the EB and WB cohorts as compared with the BB cohort (BB, 92% and 83%; EB, 96% and 90%; WB, 97% and 91%, respectively; P < .001). CONCLUSIONS: Medical prevention for POR after the first intestinal resection for CD increased significantly in the past 2 decades, alongside the use of biologicals to treat POR. These changes were associated with a significant decrease in the cumulative probability of surgical POR.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Piñero G, Mañosa M, Bastida G, et al. Time Trends in Strategies for Postoperative Crohn's Disease Management and Long-Term Surgical Recurrence: Estudio Nacional en Enfermedad Inflamatoria Intestinal Sobre Determinantes Genéticos y Ambientales (ENEIDA) Registry Data. Clin Gastroenterol Hepatol. 2026. PMID: 42456915. doi:10.1016/j.cgh.2026.06.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。